dc.contributor.author | Sun, P. | |
dc.contributor.author | Zhang, X. | |
dc.contributor.author | Zang, X. | |
dc.contributor.author | Zhou, X. | |
dc.contributor.author | Chen, Y. | |
dc.contributor.author | Arunakumara, K.K.I.U. | |
dc.contributor.author | Liang, B. | |
dc.date.accessioned | 2023-02-24T07:42:05Z | |
dc.date.available | 2023-02-24T07:42:05Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | Sun, P., Zhang, X., Zang, X., Zhou, X., Chen, Y., Arunakumara, K. K. I. U. & Liang, B., (2007). Anti-hypercalcemic effect of orally administered recombinant Saccharomyces cerevisiae expressing salmon calcitonin on hypercalcemic rats. Biotechnology letters, 29(7), 1013-1018. https://doi.org/10.1007/s10529-007-9352-3. | en_US |
dc.identifier.issn | 15736776 | |
dc.identifier.uri | http://ir.lib.ruh.ac.lk/xmlui/handle/iruor/11491 | |
dc.description.abstract | Oral delivery of salmon calcitonin (sCT) to rats via a recombinant Saccharomyces cerevisiae was assessed. A synthetic sCT gene was cloned and expressed in S. cerevisiae yAGA2- sCT. Recombinant salmon calcitonin (rsCT) expression was detected by flow cytometry. The resorption activity of osteoclasts was inhibited by 3 · 10–6 M rsCT. Oral administration of 5 g lyophilized yAGA2-sCT/kg to hypercalcemic rats decreased serum calcium from 2.8 ± 0.02– 2.7 ± 0.02 mM | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.subject | Hypercalcemia | en_US |
dc.subject | Osteoclast | en_US |
dc.subject | Saccharomyces cerevisia | en_US |
dc.subject | Salmon calcitonin | en_US |
dc.title | Anti-hypercalcemic effect of orally administered recombinant Saccharomyces cerevisiae expressing salmon calcitonin on hypercalcemic rats. | en_US |
dc.type | Article | en_US |